The quest to slow ageing through drug discovery

Area of Science:

• Gerontology and Longevity Science
• Biomedical Interventions for Aging

Background:

• Aging is a modifiable biological process.
• Interventions targeting key biological systems can slow aging phenotypes.
• These interventions show promise in delaying age-related diseases in preclinical models.

Purpose of the Study:

• To review and categorize promising interventions for slowing the aging process.
• To assess the potential and clinical trial feasibility of these anti-aging agents.
• To support the goal of extending healthspan and mitigating age-related decline.

Main Methods:

• Categorization of interventions based on preclinical and clinical evidence robustness.
• Identification of top-tier interventions including rapamycin, senolytics, metformin, acarbose, spermidine, NAD+ enhancers, and lithium.
• Evaluation of the potential therapeutic applications and clinical trial design considerations.

Main Results:

• Several interventions demonstrate significant potential to slow aging.
• Top-tier interventions identified include rapamycin, senolytics, metformin, acarbose, spermidine, NAD+ enhancers, and lithium.
• Preclinical data supports the efficacy of these agents in mitigating age-related functional decline and disease.

Conclusions:

• Targeted interventions can modify the aging process and extend healthspan.
• Further clinical research is warranted to validate these findings in humans.
• The ultimate aim is to maintain health and function longer throughout life.